SEARCH

SEARCH BY CITATION

References

  • 1
    Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial. N Engl J Med 1987;316:738.
  • 2
    Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986;2:11758.
  • 3
    Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: Dose finding and identification of predictors of response. Blood 1995;86:444653.
  • 4
    Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003;122:38693.
  • 5
    Granetto C, Ricci S, Martoni A, Pezzella G, Testore F, Mattioli R, et al. Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy. Oncol Rep 2003;10:128996.
  • 6
    Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:220116.
  • 7
    Cella D. The functional assessment of cancer therapy-anaemia (FACT-AN) scale: A new tool for the assessment of outcomes in cancer anaemia and fatigue. Semin Hematol 1997;34:139.
  • 8
    European Medicines Agency. EMEA Public statement: European medicines agency starts review of the safety of epoetins. Doc.Ref. EMEA/188068/2007-corr. London, 27 April 2007.
  • 9
    Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin—An updated overview. Nature Clin Pract Oncol 2006;3:15264.